Evotec SEEvotec SEEvotec SE

Evotec SE

No trades
No trades

Compare with Evotec SE


Market capitalization
‪699.25 M‬USD
−0.63USD
‪−116.83 M‬USD
‪889.74 M‬USD
‪336.88 M‬
Beta (1Y)
2.69
Next report date
Report period
EPS estimate
Revenue estimate

Profile


CEO
Christian Wojczewski
Website
Headquarters
Hamburg
Founded
1998
IPO date
Oct 11, 1999
ISIN
US30050E1055
CUSIP
30050E105
FIGI
BBG000LFTJ81
Identifiers
ISIN US30050E1055
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
YTM
Maturity dateMay 21, 2033
Coupon2.63% (Fixed)

See all EVO bonds